Evidence map›Paper›PMID 34808243›Full record

ArticleThe Journal of infection2022

Alpha (B.1.1.7) and Delta (B.1.617.2 - AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage.

Samuel Lebourgeois, Reyene Menidjel, Houssem Redha Chenane, Valentine Marie Ferré, Gilles Collin, Florence Damond, Romain Coppée, Yazdan Yazdanpanah, Jean-François Timsit, Nadhira Houhou-Fidouh and 3 more

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Samuel LebourgeoisService de Virologie, Hôpital Bichat Claude Bernard, Université de Paris, IAME, INSERM, 46, rue Henri Huchard, Paris F-75018, France. Electronic address: samuel.lebourgois@inserm.fr.
Reyene MenidjelService de Virologie, Hôpital Bichat Claude Bernard, Université de Paris, IAME, INSERM, 46, rue Henri Huchard, Paris F-75018, France.
Houssem Redha ChenaneService de Virologie, Hôpital Bichat Claude Bernard, Université de Paris, IAME, INSERM, 46, rue Henri Huchard, Paris F-75018, France.
Valentine Marie FerréService de Virologie, Hôpital Bichat Claude Bernard, Université de Paris, IAME, INSERM, 46, rue Henri Huchard, Paris F-75018, France; AP-HP, Service de Virologie, University Hospital Bichat-Claude Bernard, 16, rue Henri Huchard, Paris, France.
Gilles CollinService de Virologie, Hôpital Bichat Claude Bernard, Université de Paris, IAME, INSERM, 46, rue Henri Huchard, Paris F-75018, France; AP-HP, Service de Virologie, University Hospital Bichat-Claude Bernard, 16, rue Henri Huchard, Paris, France.
Florence DamondService de Virologie, Hôpital Bichat Claude Bernard, Université de Paris, IAME, INSERM, 46, rue Henri Huchard, Paris F-75018, France; AP-HP, Service de Virologie, University Hospital Bichat-Claude Bernard, 16, rue Henri Huchard, Paris, France.
Romain CoppéeService de Virologie, Hôpital Bichat Claude Bernard, Université de Paris, IAME, INSERM, 46, rue Henri Huchard, Paris F-75018, France.
Yazdan YazdanpanahService de Virologie, Hôpital Bichat Claude Bernard, Université de Paris, IAME, INSERM, 46, rue Henri Huchard, Paris F-75018, France; AP-HP, Service des Maladies Infectieuses et Tropicales, University Hospital Bichat-Claude Bernard, Paris, France.
Jean-François TimsitService de Virologie, Hôpital Bichat Claude Bernard, Université de Paris, IAME, INSERM, 46, rue Henri Huchard, Paris F-75018, France; AP-HP, Service de Réanimation Médicale et Infectieuses, University Hospital Bichat-Claude Bernard, Paris, France.
Nadhira Houhou-FidouhAP-HP, Service de Virologie, University Hospital Bichat-Claude Bernard, 16, rue Henri Huchard, Paris, France.
Diane DescampsService de Virologie, Hôpital Bichat Claude Bernard, Université de Paris, IAME, INSERM, 46, rue Henri Huchard, Paris F-75018, France; AP-HP, Service de Virologie, University Hospital Bichat-Claude Bernard, 16, rue Henri Huchard, Paris, France.
Charlotte CharpentierService de Virologie, Hôpital Bichat Claude Bernard, Université de Paris, IAME, INSERM, 46, rue Henri Huchard, Paris F-75018, France; AP-HP, Service de Virologie, University Hospital Bichat-Claude Bernard, 16, rue Henri Huchard, Paris, France.
Benoit VisseauxService de Virologie, Hôpital Bichat Claude Bernard, Université de Paris, IAME, INSERM, 46, rue Henri Huchard, Paris F-75018, France; AP-HP, Service de Virologie, University Hospital Bichat-Claude Bernard, 16, rue Henri Huchard, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19SARS-CoV-2Antibodies, NeutralizingHumansNeutralization TestsVaccinationAntibodies, NeutralizingBNT162b2 vaccineDeltaReplication rateSARS-CoV-2SeroneutralizationVaccination

Identifiers

PMID34808243
PMCPMC8603409

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.